Nikoleta G. Tsvetanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nikoleta G. Tsvetanova has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Mark von Zastrow
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco CA, USA
4 shared publications - Braden T. Lobingier
Department of Chemical Physiology and Biochemistry, Oregon Health & Science University
3 shared publications - Martin Kampmann
Institute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA
3 shared publications Andrew P. Kurland
Microbiology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publicationsAngelica Garces
Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA
2 shared publicationsBilly W. Newton
Department of Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, California, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, California, USA
2 shared publications
Latest Publications
- Open Access
GPCR endocytosis rewires neuronal gene expression and cellular architecture
In the brain, G protein-coupled receptors (GPCRs) regulate neuronal excitability, synaptic transmission, and behavior by engaging transcriptional and translational programs that produce enduring changes in cellular function and architecture. However, the molecular mechanisms that couple GPCR activation to these adaptations remain poorly understood. Here, we demonstrate that the beta-adrenergic receptor (β2AR), a mediator of noradrenaline in the central nervous system, remodels neuronal morphology through compartmentalized signaling pathways that orchestrate distinct layers of gene regulation. Following stimulation, β2ARs remain active on endosomes, and their intracellular signaling promotes dendritic growth and synapse formation. These structural effects are driven by two coordinated regulatory axes: PKA/CREB-dependent transcription of morphogenesis-related genes and PKA/mTOR-dependent translation of components of the protein synthesis machinery. Altogether, this work defines novel spatial and biochemical principles by which GPCR signaling drives structural reorganization and functional adaptations in neurons.
Open AccessGPCR endocytosis rewires neuronal gene expression and cellular architecture
In the brain, G protein-coupled receptors (GPCRs) regulate neuronal excitability, synaptic transmission, and behavior by engaging transcriptional and translational programs that produce enduring changes in cellular function and architecture. However, the molecular mechanisms that couple GPCR activation to these adaptations remain poorly understood. Here, we demonstrate that the beta-adrenergic receptor (β2AR), a mediator of noradrenaline in the central nervous system, remodels neuronal morphology through compartmentalized signaling pathways that orchestrate distinct layers of gene regulation. Following stimulation, β2ARs remain active on endosomes, and their intracellular signaling promotes dendritic growth and synapse formation. These structural effects are driven by two coordinated regulatory axes: PKA/CREB-dependent transcription of morphogenesis-related genes and PKA/mTOR-dependent translation of components of the protein synthesis machinery. Altogether, this work defines novel spatial and biochemical principles by which GPCR signaling drives structural reorganization and functional adaptations in neurons.
- 2 June 2025
- Published by Springer Nature in Nature Chemical Biology
- p. 1-12
Chemical biology approaches to resolve the subcellular GPCR signaling landscape
G-protein-coupled receptors (GPCRs) are the largest class of membrane receptors and key drug targets. Over the past decade, extensive evidence has shown that GPCRs signal from various intracellular compartments to generate distinct cellular and physiological responses. Therefore, it is critical to understand how the subcellular sites of GPCR signaling affect receptor function and pharmacology, and how the insights can be exploited to develop improved therapeutics. This Review highlights recent advances in GPCR signaling and spatiotemporal regulation with a focus on chemical biology approaches. We discuss biosensors for real-time recordings of localized GPCR responses, tools for site-selective tuning of signaling pathways, quantitative approaches to determine interactors and global cellular behaviors, reporters enabling unbiased mechanistic screening and compartment-specific ligands. We emphasize the need to develop and advance chemical biology tools to deepen our mechanistic understanding of compartmentalized GPCR signaling and fuel future drug discovery efforts.
- 2 June 2025
- Published by Springer Nature in Nature Chemical Biology
- p. 1-12
Chemical biology approaches to resolve the subcellular GPCR signaling landscape
G-protein-coupled receptors (GPCRs) are the largest class of membrane receptors and key drug targets. Over the past decade, extensive evidence has shown that GPCRs signal from various intracellular compartments to generate distinct cellular and physiological responses. Therefore, it is critical to understand how the subcellular sites of GPCR signaling affect receptor function and pharmacology, and how the insights can be exploited to develop improved therapeutics. This Review highlights recent advances in GPCR signaling and spatiotemporal regulation with a focus on chemical biology approaches. We discuss biosensors for real-time recordings of localized GPCR responses, tools for site-selective tuning of signaling pathways, quantitative approaches to determine interactors and global cellular behaviors, reporters enabling unbiased mechanistic screening and compartment-specific ligands. We emphasize the need to develop and advance chemical biology tools to deepen our mechanistic understanding of compartmentalized GPCR signaling and fuel future drug discovery efforts.
- Open Access
- 18 February 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (8)
Extensive location bias of the GPCR-dependent translatome via site-selective activation of mTOR
G protein–coupled receptors (GPCRs) modulate various physiological functions by rewiring cellular gene expression in response to extracellular signals. Control of gene expression by GPCRs has been studied almost exclusively at the transcriptional level, neglecting an extensive amount of regulation that takes place translationally. Hence, little is known about the nature and mechanisms of gene-specific posttranscriptional regulation downstream of receptor activation. Here, we apply an unbiased multiomics approach to delineate an extensive translational regulatory program initiated by the prototypical beta2-adrenergic receptor (β2-AR) and provide mechanistic insights into how these processes are orchestrated. Using ribosome profiling (Ribo-seq), we identify nearly 120 gene targets of adrenergic receptor activity for which expression is exclusively regulated at the level of translation. We next show that all translational changes are induced selectively by endosomal β2-ARs and report that this proceeds through activation of the mammalian target of rapamycin (mTOR) pathway. Specifically, within the set of translational GPCR targets, we find significant enrichment of genes with 5’ terminal oligopyrimidine (TOP) motifs, a gene class classically known to be translationally regulated by mTOR. We then demonstrate that endosomal β2-ARs are required for mTOR activation and subsequent mTOR-dependent TOP mRNA translation. This site-selective crosstalk between the pathways is observed in multiple cell models with native β2-ARs, across a range of endogenous and synthetic adrenergic agonists, and for other GPCRs with intracellular activity. Together, this comprehensive analysis of drug-induced translational regulation establishes a critical role for location-biased GPCR signaling in fine-tuning the cellular protein landscape.
- 18 February 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (8)
Open AccessExtensive location bias of the GPCR-dependent translatome via site-selective activation of mTOR
G protein–coupled receptors (GPCRs) modulate various physiological functions by rewiring cellular gene expression in response to extracellular signals. Control of gene expression by GPCRs has been studied almost exclusively at the transcriptional level, neglecting an extensive amount of regulation that takes place translationally. Hence, little is known about the nature and mechanisms of gene-specific posttranscriptional regulation downstream of receptor activation. Here, we apply an unbiased multiomics approach to delineate an extensive translational regulatory program initiated by the prototypical beta2-adrenergic receptor (β2-AR) and provide mechanistic insights into how these processes are orchestrated. Using ribosome profiling (Ribo-seq), we identify nearly 120 gene targets of adrenergic receptor activity for which expression is exclusively regulated at the level of translation. We next show that all translational changes are induced selectively by endosomal β2-ARs and report that this proceeds through activation of the mammalian target of rapamycin (mTOR) pathway. Specifically, within the set of translational GPCR targets, we find significant enrichment of genes with 5’ terminal oligopyrimidine (TOP) motifs, a gene class classically known to be translationally regulated by mTOR. We then demonstrate that endosomal β2-ARs are required for mTOR activation and subsequent mTOR-dependent TOP mRNA translation. This site-selective crosstalk between the pathways is observed in multiple cell models with native β2-ARs, across a range of endogenous and synthetic adrenergic agonists, and for other GPCRs with intracellular activity. Together, this comprehensive analysis of drug-induced translational regulation establishes a critical role for location-biased GPCR signaling in fine-tuning the cellular protein landscape.
- 2 September 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (3) , 360-370
An engineered trafficking biosensor reveals a role for DNAJC13 in DOR downregulation
Trafficking of G protein-coupled receptors (GPCRs) through the endosomal–lysosomal pathway is critical to homeostatic regulation of GPCRs following activation with agonist. Identifying the genes involved in GPCR trafficking is challenging due to the complexity of sorting operations and the large number of cellular proteins involved in the process. Here, we developed a high-sensitivity biosensor for GPCR expression and agonist-induced trafficking to the lysosome by leveraging the ability of the engineered peroxidase APEX2 to activate the fluorogenic substrate Amplex UltraRed (AUR). We used the GPCR–APEX2/AUR assay to perform a genome-wide CRISPR interference screen focused on identifying genes regulating expression and trafficking of the δ-opioid receptor (DOR). We identified 492 genes consisting of both known and new regulators of DOR function. We demonstrate that one new regulator, DNAJC13, controls trafficking of multiple GPCRs, including DOR, through the endosomal–lysosomal pathway by regulating the composition of the endosomal proteome and endosomal homeostasis.
- 2 September 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (3) , 360-370
An engineered trafficking biosensor reveals a role for DNAJC13 in DOR downregulation
Trafficking of G protein-coupled receptors (GPCRs) through the endosomal–lysosomal pathway is critical to homeostatic regulation of GPCRs following activation with agonist. Identifying the genes involved in GPCR trafficking is challenging due to the complexity of sorting operations and the large number of cellular proteins involved in the process. Here, we developed a high-sensitivity biosensor for GPCR expression and agonist-induced trafficking to the lysosome by leveraging the ability of the engineered peroxidase APEX2 to activate the fluorogenic substrate Amplex UltraRed (AUR). We used the GPCR–APEX2/AUR assay to perform a genome-wide CRISPR interference screen focused on identifying genes regulating expression and trafficking of the δ-opioid receptor (DOR). We identified 492 genes consisting of both known and new regulators of DOR function. We demonstrate that one new regulator, DNAJC13, controls trafficking of multiple GPCRs, including DOR, through the endosomal–lysosomal pathway by regulating the composition of the endosomal proteome and endosomal homeostasis.
- Open Access
Extensive location bias of the GPCR-dependent translatome via site-selective activation of mTOR
G protein-coupled receptors (GPCRs) modulate various physiological functions by re-wiring cellular gene expression in response to extracellular signals. Control of gene expression by GPCRs has been studied almost exclusively at the transcriptional level, neglecting an extensive amount of regulation that takes place translationally. Hence, little is known about the nature and mechanisms of gene-specific post-transcriptional regulation downstream of receptor activation. Here, we apply an unbiased multiomics approach to delineate an extensive translational regulatory program initiated by the prototypical beta2-adrenergic receptor (β2-AR) and provide mechanistic insights into how these processes are orchestrated. Using ribosome profiling (Ribo-seq), we identify nearly 120 novel gene targets of adrenergic receptor activity which expression is exclusively regulated at the level of translation. We next show that all translational changes are induced selectively by endosomal β2-ARs. We further report that this proceeds through activation of the mammalian target of rapamycin (mTOR) pathway. Specifically, within the set of translational GPCR targets we discover significant enrichment of genes with 5’ terminal oligopyrimidine (TOP) motifs, a gene class classically known to be translationally regulated by mTOR. We then demonstrate that endosomal β2-ARs are required for mTOR activation and subsequent mTOR-dependent TOP mRNA translation. Together, this comprehensive analysis of drug-induced translational regulation establishes a critical role for location-biased GPCR signaling in fine-tuning the cellular protein landscape.
Open AccessExtensive location bias of the GPCR-dependent translatome via site-selective activation of mTOR
G protein-coupled receptors (GPCRs) modulate various physiological functions by re-wiring cellular gene expression in response to extracellular signals. Control of gene expression by GPCRs has been studied almost exclusively at the transcriptional level, neglecting an extensive amount of regulation that takes place translationally. Hence, little is known about the nature and mechanisms of gene-specific post-transcriptional regulation downstream of receptor activation. Here, we apply an unbiased multiomics approach to delineate an extensive translational regulatory program initiated by the prototypical beta2-adrenergic receptor (β2-AR) and provide mechanistic insights into how these processes are orchestrated. Using ribosome profiling (Ribo-seq), we identify nearly 120 novel gene targets of adrenergic receptor activity which expression is exclusively regulated at the level of translation. We next show that all translational changes are induced selectively by endosomal β2-ARs. We further report that this proceeds through activation of the mammalian target of rapamycin (mTOR) pathway. Specifically, within the set of translational GPCR targets we discover significant enrichment of genes with 5’ terminal oligopyrimidine (TOP) motifs, a gene class classically known to be translationally regulated by mTOR. We then demonstrate that endosomal β2-ARs are required for mTOR activation and subsequent mTOR-dependent TOP mRNA translation. Together, this comprehensive analysis of drug-induced translational regulation establishes a critical role for location-biased GPCR signaling in fine-tuning the cellular protein landscape.
- Top Cited PapersOpen Access
- 23 January 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (3) , 105668
Functional diversification of cell signaling by GPCR localization
- 23 January 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (3) , 105668
Top Cited PapersOpen AccessFunctional diversification of cell signaling by GPCR localization
- Open Access
- 4 August 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (9) , 105133
The psychosis risk factor RBM12 encodes a novel repressor of GPCR/cAMP signal transduction
- 4 August 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (9) , 105133
Open AccessThe psychosis risk factor RBM12 encodes a novel repressor of GPCR/cAMP signal transduction
- 27 July 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (2) , 151-161
Endosome positioning coordinates spatially selective GPCR signaling
G-protein-coupled receptors (GPCRs) can initiate unique functional responses depending on the subcellular site of activation. Efforts to uncover the mechanistic basis of compartmentalized GPCR signaling have concentrated on the biochemical aspect of this regulation. Here we assess the biophysical positioning of receptor-containing endosomes as an alternative salient mechanism. We devise a strategy to rapidly and selectively redistribute receptor-containing endosomes ‘on command’ in intact cells without perturbing their biochemical composition. Next, we present two complementary optical readouts that enable robust measurements of bulk- and gene-specific GPCR/cyclic AMP (cAMP)-dependent transcriptional signaling with single-cell resolution. With these, we establish that disruption of native endosome positioning inhibits the initiation of the endosome-dependent transcriptional responses. Finally, we demonstrate a prominent mechanistic role of PDE-mediated cAMP hydrolysis and local protein kinase A activity in this process. Our study, therefore, illuminates a new mechanism regulating GPCR function by identifying endosome positioning as the principal mediator of spatially selective receptor signaling.
- 27 July 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (2) , 151-161
Endosome positioning coordinates spatially selective GPCR signaling
G-protein-coupled receptors (GPCRs) can initiate unique functional responses depending on the subcellular site of activation. Efforts to uncover the mechanistic basis of compartmentalized GPCR signaling have concentrated on the biochemical aspect of this regulation. Here we assess the biophysical positioning of receptor-containing endosomes as an alternative salient mechanism. We devise a strategy to rapidly and selectively redistribute receptor-containing endosomes ‘on command’ in intact cells without perturbing their biochemical composition. Next, we present two complementary optical readouts that enable robust measurements of bulk- and gene-specific GPCR/cyclic AMP (cAMP)-dependent transcriptional signaling with single-cell resolution. With these, we establish that disruption of native endosome positioning inhibits the initiation of the endosome-dependent transcriptional responses. Finally, we demonstrate a prominent mechanistic role of PDE-mediated cAMP hydrolysis and local protein kinase A activity in this process. Our study, therefore, illuminates a new mechanism regulating GPCR function by identifying endosome positioning as the principal mediator of spatially selective receptor signaling.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 150
Multiomics approach to interrogate translational regulation to GPCR signaling and its spatial bias
ID 16887 Poster Board 150 Ligand activation of G protein-coupled receptors (GPCRs) induces a plethora of cellular responses that ultimately culminate in changes in protein expression. Our lab and others have demonstrated that certain GPCR-dependent responses that feed into protein expression changes are biased by receptor localization. Specifically, we have shown that gene transcription is stimulated downstream of endosomal receptors. However, transcription represents only one layer of gene expression regulation, and therefore analysis of steady-state RNA abundance alone does not adequately capture the full breadth of changes that underlie protein expression. To address this, we apply a multiomics approach to interrogate the comprehensive landscape of transcriptional and post-transcriptional changes in cellular responsiveness to receptor activation, and assess their dependence on GPCR localization. We pair RNA-seq and Ribo-seq and identify hundreds of target genes downstream of the prototypical beta-2-adrenergic receptor (B2AR) to be regulated exclusively at the transcriptional or translational level. Strikingly, none of the translational targets identified here have been previously linked to GPCR signaling. In addition, we find distinct functional categories over-represented across each set of targets (transcriptional vs translational), suggesting that unique cellular processes downstream of B2AR activation are subject to discrete regulatory mechanisms. In further studies, we show that the vast majority of these genes likely represent conserved translational targets downstream of Gas-coupled receptors. Lastly, we are probing the spatial dependence of the novel translational targets. In preliminary work, we have identified genes encoding complexes involved in iron homeostasis as exclusive translational targets, and show that at least one of these genes requires endosomal B2AR signaling for its translational regulation. These mechanisms are of broad biological relevance as they appear to be conserved in both tractable and physiologically-relevant adrenoceptor cell types such as iPSC-derive human CMs. In summary, we have successfully developed an experimental pipeline to probe gene expression regulation at multiple levels. This work is extending our understanding of the cellular processes dependent on compartmentalized receptor signaling and their underlying regulation.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 150
Open AccessMultiomics approach to interrogate translational regulation to GPCR signaling and its spatial bias
ID 16887 Poster Board 150 Ligand activation of G protein-coupled receptors (GPCRs) induces a plethora of cellular responses that ultimately culminate in changes in protein expression. Our lab and others have demonstrated that certain GPCR-dependent responses that feed into protein expression changes are biased by receptor localization. Specifically, we have shown that gene transcription is stimulated downstream of endosomal receptors. However, transcription represents only one layer of gene expression regulation, and therefore analysis of steady-state RNA abundance alone does not adequately capture the full breadth of changes that underlie protein expression. To address this, we apply a multiomics approach to interrogate the comprehensive landscape of transcriptional and post-transcriptional changes in cellular responsiveness to receptor activation, and assess their dependence on GPCR localization. We pair RNA-seq and Ribo-seq and identify hundreds of target genes downstream of the prototypical beta-2-adrenergic receptor (B2AR) to be regulated exclusively at the transcriptional or translational level. Strikingly, none of the translational targets identified here have been previously linked to GPCR signaling. In addition, we find distinct functional categories over-represented across each set of targets (transcriptional vs translational), suggesting that unique cellular processes downstream of B2AR activation are subject to discrete regulatory mechanisms. In further studies, we show that the vast majority of these genes likely represent conserved translational targets downstream of Gas-coupled receptors. Lastly, we are probing the spatial dependence of the novel translational targets. In preliminary work, we have identified genes encoding complexes involved in iron homeostasis as exclusive translational targets, and show that at least one of these genes requires endosomal B2AR signaling for its translational regulation. These mechanisms are of broad biological relevance as they appear to be conserved in both tractable and physiologically-relevant adrenoceptor cell types such as iPSC-derive human CMs. In summary, we have successfully developed an experimental pipeline to probe gene expression regulation at multiple levels. This work is extending our understanding of the cellular processes dependent on compartmentalized receptor signaling and their underlying regulation.
- Open Access
The psychosis risk factor RBM12 encodes a novel repressor of GPCR/cAMP signal transduction
RBM12 is a high-penetrance risk factor for familial schizophrenia and psychosis, yet its precise cellular functions and the pathways to which it belongs are not known. We utilize two complementary models, HEK293 cells and human iPSC-derived neurons, and delineate RBM12 as a novel repressor of the G protein-coupled receptor/cyclic AMP/protein kinase A (GPCR/cAMP/PKA) signaling axis. We establish that loss of RBM12 leads to hyperactive cAMP production and increased PKA activity as well as altered neuronal transcriptional responses to GPCR stimulation. Notably, the cAMP and transcriptional signaling steps are subject to discrete RBM12-dependent regulation. We further demonstrate that the two RBM12 truncating variants linked to familial psychosis impact this interplay, as the mutants fail to rescue GPCR/cAMP signaling hyperactivity in cells depleted of RBM12. Lastly, we present a mechanism underlying the impaired signaling phenotypes. In agreement with its activity as an RNA-binding protein, loss of RBM12 leads to altered gene expression, including that of multiple effectors of established significance within the receptor pathway. Specifically, the abundance of adenylyl cyclases, phosphodiesterase isoforms, and PKA regulatory and catalytic subunits is impacted by RBM12 depletion. We note that these expression changes are fully consistent with the entire gamut of hyperactive signaling outputs. In summary, the current study identifies a previously unappreciated role for RBM12 in the context of the GPCR/cAMP pathway that could be explored further as a tentative molecular mechanism underlying the functions of this factor in neuronal physiology and pathophysiology.
Open AccessThe psychosis risk factor RBM12 encodes a novel repressor of GPCR/cAMP signal transduction
RBM12 is a high-penetrance risk factor for familial schizophrenia and psychosis, yet its precise cellular functions and the pathways to which it belongs are not known. We utilize two complementary models, HEK293 cells and human iPSC-derived neurons, and delineate RBM12 as a novel repressor of the G protein-coupled receptor/cyclic AMP/protein kinase A (GPCR/cAMP/PKA) signaling axis. We establish that loss of RBM12 leads to hyperactive cAMP production and increased PKA activity as well as altered neuronal transcriptional responses to GPCR stimulation. Notably, the cAMP and transcriptional signaling steps are subject to discrete RBM12-dependent regulation. We further demonstrate that the two RBM12 truncating variants linked to familial psychosis impact this interplay, as the mutants fail to rescue GPCR/cAMP signaling hyperactivity in cells depleted of RBM12. Lastly, we present a mechanism underlying the impaired signaling phenotypes. In agreement with its activity as an RNA-binding protein, loss of RBM12 leads to altered gene expression, including that of multiple effectors of established significance within the receptor pathway. Specifically, the abundance of adenylyl cyclases, phosphodiesterase isoforms, and PKA regulatory and catalytic subunits is impacted by RBM12 depletion. We note that these expression changes are fully consistent with the entire gamut of hyperactive signaling outputs. In summary, the current study identifies a previously unappreciated role for RBM12 in the context of the GPCR/cAMP pathway that could be explored further as a tentative molecular mechanism underlying the functions of this factor in neuronal physiology and pathophysiology.